"Will it show up?" is two questions wearing one coat. The first is analytical: does the test being run look for this compound, and can its method see it? The second is a rules question: is the compound prohibited for the person being tested? For peptides the answers point in opposite directions depending on who is testing, which is why forum answers contradict each other. This page takes each test in turn and cites what the labs and the rule-makers have published. It reports research on research compounds as journalism; it contains no usage guidance, in line with our editorial standards.
Three kinds of test, three answers
| Test | What it looks for | Are peptides on it? | Are peptides prohibited for the person tested? |
|---|---|---|---|
| Workplace urinalysis (employer, DOT, federal) | Drugs of abuse by immunoassay, confirmed by mass spectrometry | No | Usually not a workplace matter; depends on employer policy |
| Military urinalysis (DoD Drug Demand Reduction Program) | Drugs of abuse, updated by memorandum: fentanyl added 2019, psilocin 2025 | No | Yes for listed ingredients such as BPC-157, under DoDI 6130.06, regardless of testing |
| Anti-doping (WADA code signatories, USADA, NCAA) | Named prohibited substances, including peptides, by mass spectrometry in urine and blood | Yes, by name and metabolite | Yes, at all times, with strict liability |
Workplace and military panels: built for other drugs
A standard urine drug screen is an immunoassay aimed at a short list of drug classes, confirmed by chromatography when positive. The federal workplace program's panel is set by the HHS Mandatory Guidelines and concerns drugs of abuse; peptides are not on it, and an antibody raised against a cocaine metabolite does not bind a growth-hormone secretagogue. Employer panels are variants of the federal one.
The Department of Defense runs the largest urinalysis program in the country and publishes its changes. In March 2019 the department directed "all service Drug Demand Reduction Program labs to test for fentanyl and norfentanyl", and "the five service branch DDRPs and the AFMES SFTDTL began fentanyl screening in June 2019" (DVIDS, 2019-11-21). From 2025-10-01 psilocin, the active metabolite of psilocybin, joined the panel; the announcement described the routine tests as focused on "substances like marijuana, cocaine, amphetamines, and opioids" (Military.com, 2025-09-26). The panel is a list of analytes and cut-offs that the department updates by memorandum; no peptide has been added to it.
That is the analytical answer. The rules answer for Service Members is different. BPC-157 is on the DoD Prohibited Dietary Supplement Ingredients List, maintained under DoD Instruction 6130.06 and updated on 2026-05-26. Operation Supplement Safety, the department's program, describes BPC-157 as "a laboratory-made synthetic peptide", notes that products carrying it "might" be labeled "Not for human consumption", "Research use only" or "For research purposes only", and states: "Service Members should avoid using 'research chemicals' or any products containing prohibited ingredients" (OPSS, 2025-04-29). The route to trouble is a supplement inspection, a medical encounter, a purchase record or a report, not a urinalysis cup.
Anti-doping: the list
The World Anti-Doping Agency's 2026 Prohibited List took effect on 2026-01-01. The peptides people ask about sit in three places on it, all marked "prohibited at all times (in- and out-of-competition)":
- S0, Non-approved substances: any pharmacological substance not addressed elsewhere on the list and not approved by a government health authority for human therapeutic use, with BPC-157 among the named examples.
- S2.2.4, Growth hormone releasing factors: GHRH and its analogues (CJC-1293, CJC-1295, sermorelin, tesamorelin); growth hormone secretagogues and their mimetics (anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin, macimorelin, tabimorelin); and GH-releasing peptides (alexamorelin, examorelin (hexarelin), GHRP-1 through GHRP-6, GHRP-2 also called pralmorelin).
- S2.3, Growth factors and growth factor modulators: insulin-like growth factor 1 (IGF-1) and its analogues, thymosin-β4 and its derivatives such as TB-500, and others.
Anti-myostatin agents and activin-receptor blockers such as ACE-031 are in S4.3. The list is published as the official English text on WADA's site; the wording above is from the 2026 List (WADA Prohibited List).
The NCAA's banned-drug classes for 2026-27 take the same shape in fewer words. Under "Peptide Hormones, growth factors, related substances and mimetics" the named examples are "BPC-157, Erythropoietin (EPO), Growth hormone (hGH), Human Chorionic Gonadotropin (hCG), Ibutamoren (MK-677), IGF-1 (colostrum; deer antler velvet), TB-500", with the note that "Any substance that is chemically/pharmacologically related to one of the above drug classes, even if it is not listed as an example, is also banned" (NCAA banned substances).
Anti-doping: the method
Being on the list is one thing; being findable is another, and for small peptides the labs have solved it. The published work is by accredited anti-doping laboratories and reads as follows.
Screening. A 2016 method from the Cologne laboratory injects urine directly into a liquid chromatograph coupled to ion-mobility time-of-flight mass spectrometry and screens, in one run, for peptides under 2 kDa on the Prohibited List: "Desmopressin, LH-RH, Buserelin, Triptorelin, Leuprolide, GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5, GHRP-6, Alexamorelin, Ipamorelin, Hexarelin, ARA-290, AOD-9604, TB-500 and Anamorelin". Limits of detection were "between 50 and 500 pg/mL", which "covers the minimum required performance level of 2 ng/mL" that WADA sets for these compounds, and the method was proven on elimination samples from people who had taken GHRP-6, GHRP-2 or LHRH (Thomas et al., Journal of Separation Science 2016).
Metabolites and windows. The Moscow anti-doping laboratory gave GHRP-1, GHRP-2, GHRP-6, hexarelin and ipamorelin nasally, one compound to one volunteer each, and followed urine for two days. GHRP-1 was not found as the parent compound at all; its metabolite was detectable "up to 27 h". GHRP-2 and two metabolites were detectable "up to 47 h". GHRP-6 was "mostly excreted unchanged and detected in urine 23 h after administration, its metabolites were detectable for 12 h only". Hexarelin and ipamorelin "metabolized intensively" and their fragments "were detected in urine samples after complete withdrawal of parent substances". The authors' conclusion is the one to keep: "the detection window after GHRPs administration depends on individual metabolism, drug preparation form and the way of administration" (Semenistaya et al., Drug Testing and Analysis 2016). One volunteer per compound, by nose, is a method-development study, not a population estimate, and it is the best published data there is.
Blood, including dried spots. In 2026 the Ghent laboratory published a single-extraction workflow that detects 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum and plasma, with detection limits of 0.05 to 1.25 ng/mL, and tested it on samples containing sub-nanogram levels of ibutamoren. Stability is the practical finding: in liquid serum "BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation" at room temperature within a week, but "in dried matrices all compounds remained detectable throughout the entire duration of the study", so that samples "can be transported and stored under non-refrigerated conditions" (Mazzarino et al., The Analyst 2026). Dried blood spots are now part of WADA testing; a peptide that would have degraded in a warm serum tube does not degrade on a card.
What is not published: a urinary detection window for BPC-157 or TB-500 from an administration study. Their presence on the screening lists means the labs can see them; how long after use is not in the open literature.
Strict liability, and the supplement route
Under the WADA code and the NCAA rules the athlete is responsible for what is found in the sample, whatever the label said and whatever they intended. The realistic route to a peptide finding for someone who never bought a vial is a product sold as a supplement. The NCAA's own list flags "colostrum; deer antler velvet" as IGF-1 sources. OPSS titled its BPC-157 article "A Prohibited Peptide and an Unapproved Drug Found in Health and Wellness Products", which is a statement about where the department has found it. FDA's compounding list, updated 2026-04-22, places GHRP-2, GHRP-6, ibutamoren and ipamorelin in category 2, substances that "may pose risk for immunogenicity" or, for ibutamoren, "significant safety risks due to the potential for congestive heart failure", which is the regulator's view of the same compounds outside sport (FDA).
Third-party certification programs test finished products against the WADA list; they reduce the risk of an undeclared peptide and do not remove it.
What the row on our ledger says
Every compound row on the muscle-growth evidence ledger carries its WADA section for this reason. The answer to "will it show up" is: not on the test your employer or your unit runs, because those tests are not looking; yes on an anti-doping test, because those labs are, at picogram sensitivity, in urine and dried blood; and for Service Members, the rule applies whether or not any test does.
Sources and dates
Opened 2026-09-05: the 2026 WADA Prohibited List (effective 2026-01-01); the NCAA 2026-27 banned-drug classes; OPSS on BPC-157 (2025-04-29) and the DoD Prohibited Dietary Supplement Ingredients List (updated 2026-05-26); DVIDS on fentanyl testing (2019-11-21); Military.com on psilocin (2025-09-26); Thomas et al. 2016 (PubMed 26578461); Semenistaya et al. 2016 (PubMed 25869809); Mazzarino et al. 2026 (PubMed 42328738); FDA's category 2 bulk-substances page (updated 2026-04-22). We could not open DoD Instruction 1010.01, the military testing policy itself, or the HHS Mandatory Guidelines page on 2026-09-05; statements about those panels rest on the department's own announcements linked above. Corrections go to the contact page.